好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Anticoagulation Failure with Supratherapeutic International Normalized Ratio in Malignancy and Ischemic Stroke
General Neurology
P5 - Poster Session 5 (8:00 AM-9:00 AM)
6-012
The objective is this article to is to understand the anti-coagulation failure and replacement with alternative medication to avoid the systemic venous thrombosis. 
Cancer-associated venous thrombo-embolism carries a high mortality and morbidity. The adherence to LMWH by the patient has made it a less popular choice and tendency to use the novel oral anticoagulants (NOACs). The progression of venous thrombo-embolism (VTE) can occur despite being on vitamin K antagonist (VKA) or novel oral anti-coagulant (NOAC).
Case report

We present a case of a 78 years old man who was suffering from worsening shortness of breath and cramping lower abdominal pain for last 4 days. The computed tomography (CT) scan of chest showed some pulmonary nodules of 5mm in size and a pancreatic neck mass 3.7 x 3.5 cm with hepatic metastases, ascites, 3.4 cm abdominal aortic aneurysm. Ultrasound Doppler of lower extremities showed echogenic thrombus within the right lower extremity from the common femoral vein through the popliteal vein. The patient was already on warfarin for atrial fibrillation on admission and presented with supra-therapeutic international normalized ratio (INR) but without any bleeding event. Later,  he developed right upper extremity weakness and left sided hemianopsia that led to computed tomography (CT) angiography of head which showed right occipital acute infarction. Despite transitioning to LMWH from the VKA, the patient suffered from ischemic stroke. The VKA treatment can lead to recurrent thrombosis despite the supra-therapeutic INR with malignancy highlighting an anti-coagulation failure. 

The patients with supra-therapeutic INR on VKAs prophylaxis can still develop diffuse cancer-associated systemic venous thrombosis and the anticoagulation failure. The use of LMWH or NOACs should be considered for at least 6 months in patients with cancer-associated VTE. Beyond 6 months, NOACs can be considered based on the creatinine clearance of the patient. 
Authors/Disclosures
Swaroopa Pulivarthi, MD, MBBS, MBA (Mischer neurosceince associates)
PRESENTER
Dr. Pulivarthi has nothing to disclose.
Salman Assad, MD, MBBS Dr. Assad has nothing to disclose.
Mehar Zahid, MBBS Dr. Zahid has nothing to disclose.
No disclosure on file
Salman Assad, MD, MBBS Dr. Assad has nothing to disclose.